Literature DB >> 9717851

Health and disease management: what is it and where is it going? What is the role of health and disease management in hypertension?

D B Bernard1, R R Townsend, M F Sylvestri.   

Abstract

Health and disease management, a clinical improvement process that integrates best practice principles in a comprehensive manner throughout the entire continuum of care, is likely to be the dominant style of health care delivery in the future. The goal of these programs is to eliminate or reduce unacceptable variations in cost and quality between various providers by developing guidelines that will achieve measurable outcomes for specific diseases. These protocols also emphasize wellness and disease prevention, coordinate resources across the entire continuum of care, and define interventions for the entire duration of the disease. Conditions most suited to this management strategy include diseases that are of high volume and cost, complex to manage, and present chronically over a long period of the patient's life. Such programs are developed by a multidisciplinary team that is also charged with obtaining buy-in and championing the program to their peers. Among the many components of a comprehensive health and disease management program, intensive education for patients and families and altering physician behavior to obtain compliance are key areas on which to focus. Hypertension is an ideal condition to manage in this way. It is frequently the most common reason for patients to be seen by a primary care provider, is an expensive disease to treat, and is an important cause of major organ damage from inadequate treatment. Successfully adopting a disease management model for hypertension treatment that will integrate all health care providers and offer intensive education of patients and providers to encourage adherence to the highly effective therapies currently available should afford a major opportunity for a dramatic reduction in complications and costs, with enhanced clinical outcomes and quality of life for these patients.

Entities:  

Mesh:

Year:  1998        PMID: 9717851     DOI: 10.1016/s0895-7061(98)00103-4

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  6 in total

Review 1.  Pharmacoeconomics of hypertension management: the place of combination therapy.

Authors:  E Ambrosioni
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

2.  Prevalence of uncontrolled hypertension in primary care settings in Al seeb wilayat, oman.

Authors:  Rashid Al-Saadi; Sulaiman Al-Shukaili; Suleiman Al-Mahrazi; Zakiya Al-Busaidi
Journal:  Sultan Qaboos Univ Med J       Date:  2011-08-15

Review 3.  Pharmacoeconomic burden of undertreating hypertension.

Authors:  Luca Degli Esposti; Giorgia Valpiani
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

4.  Hypertension control and co-morbidities in primary health care centers in Riyadh.

Authors:  Abdulmohsin A Al-Tuwijri; Mohammed Othman Al-Rukban
Journal:  Ann Saudi Med       Date:  2006 Jul-Aug       Impact factor: 1.526

5.  The Prevalence of Uncontrolled Hypertension among Patients Taking Antihypertensive Medications and the Associated Risk Factors in North Palestine: A Cross-Sectional Study.

Authors:  Issa S Alawneh; Ahmad Yasin; Samar Musmar
Journal:  Adv Med       Date:  2022-08-25

6.  Cost-utility analysis of a national project to reduce hypertension in Israel.

Authors:  Chaim Yosefy; Gary Ginsberg; Reuven Viskoper; Dror Dicker; Dov Gavish
Journal:  Cost Eff Resour Alloc       Date:  2007-11-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.